Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A third dose of mRNA-1273 vaccine improves SARS-CoV-2 immunity in HCT recipients with low antibody response after 2 doses

24 Jan 2022

Abstract excerpt

Patients with hematologic malignancies treated with autologous (auto) and allogeneic (allo) hematopoietic cell transplantation (HCT) are at high risk of developing adverse outcomes related to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection due to immune dysregulation, prolonged immunosuppression, graft-versus-host disease (GVHD), and cytopenias.1 The estimated incidence of SARS-CoV-2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Clinical Research Studies
Share to Long-Term Effects of COVID-19
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35073574
DOI: 10.1182/bloodadvances.2021006599

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A third dose of mRNA-1273 vaccine improves SARS-CoV-2 immunity in HCT recipients with low antibody response after 2 dosesPMID 35073574Read ↗

Three-dose mRNA-1273 vaccination schedule: sufficient antibody response in majority of immunocompromised hematology patientsSemantic proximity Read ↗

SARS-CoV-2 T-Cell Responses in Allogeneic Hematopoietic Stem Cell Recipients following Two Doses of BNT162b2 mRNA VaccineSemantic proximity Read ↗

Humoral immune responses against SARS-CoV-2 variants including omicron in solid organ transplant recipients after three doses of a COVID-19 mRNA vaccineSemantic proximity Read ↗

Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell TherapySemantic proximity Read ↗

Serological Response in Lung Transplant Recipients after Two Doses of SARS-CoV-2 mRNA VaccinesSemantic proximity Read ↗

Immunogenicity and safety of the BNT162b2 mRNA COVID‐19 vaccine in haematopoietic stem cell transplantation recipientsSemantic proximity Read ↗

B and T cell responses after a third dose of SARS-CoV-2 vaccine in Kidney Transplant RecipientsSemantic proximity Read ↗

Antibody and T-cell response to a third dose of SARS-CoV-2 mRNA BNT162b2 vaccine in kidney transplant recipientsSemantic proximity Read ↗

Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipientsSemantic proximity Read ↗

Previous SARS-CoV-2 infection or a third dose of vaccine elicited cross-variant neutralizing antibodies in vaccinated solid organ transplant recipientsSemantic proximity Read ↗

Diminished antibody response against SARS-CoV-2 Omicron variant after third dose of mRNA vaccine in kidney transplant recipientsSemantic proximity Read ↗

SARS-CoV-2 Vaccine Non-response among Hematopoietic Stem Cell Transplant Patients: A Systematic Review and Meta-analysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.